ZEN-3694 is under clinical development by Zenith Epigenetics and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) ...

Unfortunately, Jamie was recently diagnosed with Nut (Midline) Carcinoma cancer — a terminal, and aggressive variant of the disease that has forced her to take a leave of absence from work while ...